Stevanato Group Spa Stock

$22.88

0.09% yesterday

NYSE, Aug 21, 10:10 pm CET

ISIN

IT0005452658

Symbol

STVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Stevanato Group Spa Stock price

$22.85

+3.18 16.17% 5Y

NYSE, Closing price Thu, Aug 21 2025

-0.05 0.22%

ISIN

IT0005452658

Symbol

STVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$6.2b

Enterprise Value

$6.6b

Net debt

$372.4m

Cash

$109.3m

Shares outstanding

272.9m

Valuation (TTM | estimate)

P/E

40.1 | 36.5

P/S

4.7 | 4.5

EV/Sales

5.0 | 4.7

EV/FCF

negative

P/B

3.8

Dividends

DPS

$0.06

Yield 1Y | 5Y

0.3% | 0.2%

Growth 1Y | 5Y

7.1% | -

Payout 1Y | 3Y

12.4% | 10.0%

Increased

1 Year

Financials (TTM | estimate)

Revenue

$1.3b | $1.4b

EBITDA

$242.8m | $346.1m

EBIT

$228.2m | $227.9m

Net Income

$156.2m | $171.0m

Free Cash Flow

$-74.4m

Growth (TTM | estimate)

Revenue

5.3% | 8.6%

EBITDA

5.1% | 53.9%

EBIT

6.2% | 8.6%

Net Income

9.5% | 25.1%

Free Cash Flow

75.1%

Financial Health

Equity Ratio

60.3%

Return on Equity

8.4%

ROCE

10.5%

ROIC

8.0%

Debt/Equity

0.3

EPS

$0.6

FCF per Share

$-0.3

Short interest

4.1%

Employees

Rev per Employee

$230.0k

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Stevanato Group Spa Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Stevanato Group Spa forecast:

13x Buy

76%

4x Hold

24%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Stevanato Group Spa forecast:

Buy

76%

Hold

24%

Analyst Estimates with Stock Price Targets

Financial data from Stevanato Group Spa

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	1,329 1,329	5% 5% 100%
- Direct Costs	946 946	7% 7% 71%
Gross Profit	383 383	1% 1% 29%
- Selling and Administrative Expenses	126 126	7% 7% 10%
- Research and Development Expense	24 24	38% 38% 2%
EBITDA	243 243	5% 5% 18%
- Depreciation and Amortization	15 15	9% 9% 1%
EBIT (Operating Income) EBIT	228 228	6% 6% 17%
Net Profit	156 156	9% 9% 12%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Stevanato Group Spa Stock News

Neutral

Business Wire

●

17 days ago

Stevanato Group Reports Revenue of €280.0 Million for the Second Quarter of 2025

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0...

Neutral

Business Wire

●

30 days ago

Stevanato Group Secures €200 Million in Financing from BNL BNP Paribas, Cassa Depositi e Prestiti, and Banco BPM to Fund Ongoing CAPEX Investments in Italy and the U.S.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it has secured €200 million in financing through agreements with BNL BNP Paribas, Cassa Depositi e Prestiti (CDP), and Banco BPM. These fundings are inte...

Neutral

Business Wire

●

about one month ago

Stevanato Group to Report Second Quarter 2025 Financial Results on August 5, 2025

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2025 on Tuesday, August 5, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Co...

More Stevanato Group Spa News

Company Profile

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates in Biopharmaceutical and Diagnostic Solutions and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Head office	Italy
CEO	Franco Stevanato
Employees	5,521
Founded	1996
Website	www.stevanatogroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now